Cost-effectiveness of influenza vaccine strategies for the elderly in South Korea

Jae Won Yun, Min Joo Choi, Gyeong Seon Shin, Jae Ok Lim, Ji Yun Noh, Yun Kyung Kim, Joon-Young Song, Woo Joo Kim, Sang Eun Choi, Hee-Jin Cheong

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives Despite a high vaccine uptake rate of over 80% in South Korea, the disease burden of influenza is still high among the elderly, which may be due to low effectiveness of vaccines. Therefore, the cost-effectiveness of use among the elderly was analyzed in order to compare the current trivalent influenza vaccine (TIV) with a quadrivalent influenza vaccine (QIV) or MF59-adjuvanted trivalent influenza vaccine (ATIV). Methods A static lifetime Markov model was used. It was assumed that the model would be repeated until individuals reached the age of 100. Cost-effectiveness was analyzed across three age groups (65-74 years, 75-84 years, and 85 years), and the at-risk group was studied. Results Compared to the TIV, the QIV was expected to reduce the number of influenza infections by 342,873, complications by 17,011, hospitalizations by 8,568, and deaths by 2,031. The QIV was highly cost-effective when compared to the TIV, with a base case incremental cost-effectiveness ratio (ICER) estimated at USD 17,699/QALY (1USD = 1,151KRW), and the ICER decreased with age and was USD 3,431/QALY in the group aged 85 and above. Sensitivity analysis revealed that the ICER was sensitive to the QIV price, the proportion of influenza B, and vaccine mismatching. On the other hand, the ATIV was expected to reduce the number of influenza cases and complications by 1,812,395 and 89,747, respectively, annually, yielding cost-saving among all ages. ATIV price and vaccine efficacy were the most influential parameters for the ICER of ATIV. Conclusions The QIV and ATIV strategies were considered more cost-effective in comparison to the TIV for vaccination strategies implemented for the elderly. However, owing to a lack of data on the effectiveness of ATIV among the elderly, a large-scale effectiveness study is required.

Original languageEnglish
Article numbere0209643
JournalPLoS One
Volume14
Issue number1
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Republic of Korea
Influenza Vaccines
South Korea
cost effectiveness
Cost effectiveness
influenza
Cost-Benefit Analysis
vaccines
Vaccines
Human Influenza
Quality-Adjusted Life Years
Costs and Cost Analysis
Costs
burden of disease

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Cost-effectiveness of influenza vaccine strategies for the elderly in South Korea. / Yun, Jae Won; Choi, Min Joo; Shin, Gyeong Seon; Lim, Jae Ok; Noh, Ji Yun; Kim, Yun Kyung; Song, Joon-Young; Kim, Woo Joo; Choi, Sang Eun; Cheong, Hee-Jin.

In: PLoS One, Vol. 14, No. 1, e0209643, 01.01.2019.

Research output: Contribution to journalArticle

@article{2835543da015485db85b36fba402e66a,
title = "Cost-effectiveness of influenza vaccine strategies for the elderly in South Korea",
abstract = "Objectives Despite a high vaccine uptake rate of over 80{\%} in South Korea, the disease burden of influenza is still high among the elderly, which may be due to low effectiveness of vaccines. Therefore, the cost-effectiveness of use among the elderly was analyzed in order to compare the current trivalent influenza vaccine (TIV) with a quadrivalent influenza vaccine (QIV) or MF59-adjuvanted trivalent influenza vaccine (ATIV). Methods A static lifetime Markov model was used. It was assumed that the model would be repeated until individuals reached the age of 100. Cost-effectiveness was analyzed across three age groups (65-74 years, 75-84 years, and 85 years), and the at-risk group was studied. Results Compared to the TIV, the QIV was expected to reduce the number of influenza infections by 342,873, complications by 17,011, hospitalizations by 8,568, and deaths by 2,031. The QIV was highly cost-effective when compared to the TIV, with a base case incremental cost-effectiveness ratio (ICER) estimated at USD 17,699/QALY (1USD = 1,151KRW), and the ICER decreased with age and was USD 3,431/QALY in the group aged 85 and above. Sensitivity analysis revealed that the ICER was sensitive to the QIV price, the proportion of influenza B, and vaccine mismatching. On the other hand, the ATIV was expected to reduce the number of influenza cases and complications by 1,812,395 and 89,747, respectively, annually, yielding cost-saving among all ages. ATIV price and vaccine efficacy were the most influential parameters for the ICER of ATIV. Conclusions The QIV and ATIV strategies were considered more cost-effective in comparison to the TIV for vaccination strategies implemented for the elderly. However, owing to a lack of data on the effectiveness of ATIV among the elderly, a large-scale effectiveness study is required.",
author = "Yun, {Jae Won} and Choi, {Min Joo} and Shin, {Gyeong Seon} and Lim, {Jae Ok} and Noh, {Ji Yun} and Kim, {Yun Kyung} and Joon-Young Song and Kim, {Woo Joo} and Choi, {Sang Eun} and Hee-Jin Cheong",
year = "2019",
month = "1",
day = "1",
doi = "10.1371/journal.pone.0209643",
language = "English",
volume = "14",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - Cost-effectiveness of influenza vaccine strategies for the elderly in South Korea

AU - Yun, Jae Won

AU - Choi, Min Joo

AU - Shin, Gyeong Seon

AU - Lim, Jae Ok

AU - Noh, Ji Yun

AU - Kim, Yun Kyung

AU - Song, Joon-Young

AU - Kim, Woo Joo

AU - Choi, Sang Eun

AU - Cheong, Hee-Jin

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objectives Despite a high vaccine uptake rate of over 80% in South Korea, the disease burden of influenza is still high among the elderly, which may be due to low effectiveness of vaccines. Therefore, the cost-effectiveness of use among the elderly was analyzed in order to compare the current trivalent influenza vaccine (TIV) with a quadrivalent influenza vaccine (QIV) or MF59-adjuvanted trivalent influenza vaccine (ATIV). Methods A static lifetime Markov model was used. It was assumed that the model would be repeated until individuals reached the age of 100. Cost-effectiveness was analyzed across three age groups (65-74 years, 75-84 years, and 85 years), and the at-risk group was studied. Results Compared to the TIV, the QIV was expected to reduce the number of influenza infections by 342,873, complications by 17,011, hospitalizations by 8,568, and deaths by 2,031. The QIV was highly cost-effective when compared to the TIV, with a base case incremental cost-effectiveness ratio (ICER) estimated at USD 17,699/QALY (1USD = 1,151KRW), and the ICER decreased with age and was USD 3,431/QALY in the group aged 85 and above. Sensitivity analysis revealed that the ICER was sensitive to the QIV price, the proportion of influenza B, and vaccine mismatching. On the other hand, the ATIV was expected to reduce the number of influenza cases and complications by 1,812,395 and 89,747, respectively, annually, yielding cost-saving among all ages. ATIV price and vaccine efficacy were the most influential parameters for the ICER of ATIV. Conclusions The QIV and ATIV strategies were considered more cost-effective in comparison to the TIV for vaccination strategies implemented for the elderly. However, owing to a lack of data on the effectiveness of ATIV among the elderly, a large-scale effectiveness study is required.

AB - Objectives Despite a high vaccine uptake rate of over 80% in South Korea, the disease burden of influenza is still high among the elderly, which may be due to low effectiveness of vaccines. Therefore, the cost-effectiveness of use among the elderly was analyzed in order to compare the current trivalent influenza vaccine (TIV) with a quadrivalent influenza vaccine (QIV) or MF59-adjuvanted trivalent influenza vaccine (ATIV). Methods A static lifetime Markov model was used. It was assumed that the model would be repeated until individuals reached the age of 100. Cost-effectiveness was analyzed across three age groups (65-74 years, 75-84 years, and 85 years), and the at-risk group was studied. Results Compared to the TIV, the QIV was expected to reduce the number of influenza infections by 342,873, complications by 17,011, hospitalizations by 8,568, and deaths by 2,031. The QIV was highly cost-effective when compared to the TIV, with a base case incremental cost-effectiveness ratio (ICER) estimated at USD 17,699/QALY (1USD = 1,151KRW), and the ICER decreased with age and was USD 3,431/QALY in the group aged 85 and above. Sensitivity analysis revealed that the ICER was sensitive to the QIV price, the proportion of influenza B, and vaccine mismatching. On the other hand, the ATIV was expected to reduce the number of influenza cases and complications by 1,812,395 and 89,747, respectively, annually, yielding cost-saving among all ages. ATIV price and vaccine efficacy were the most influential parameters for the ICER of ATIV. Conclusions The QIV and ATIV strategies were considered more cost-effective in comparison to the TIV for vaccination strategies implemented for the elderly. However, owing to a lack of data on the effectiveness of ATIV among the elderly, a large-scale effectiveness study is required.

UR - http://www.scopus.com/inward/record.url?scp=85060541681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060541681&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0209643

DO - 10.1371/journal.pone.0209643

M3 - Article

C2 - 30682030

AN - SCOPUS:85060541681

VL - 14

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e0209643

ER -